Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Blood (2024) 144 (Supplement 1): 2621.

https://doi.org/10.1182/blood-2024-202956

Published: 2024

Journal Articles

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Midori Shima, Katsuyuki Fukutake, Masanori Matsumoto, Yoshihiko Sugimura, Chiaki Sugita, Lyu Ji, Mika Kawano, Tadashi Matsushita

Blood (2024) 144 (Supplement 1): 2583.

https://doi.org/10.1182/blood-2024-193353

Published: 2024

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting: A Single Institute Retrospective Analysis

Atsushi Otani, Shinichi Ochi, Masami Yamamoto, Shota Yamaguchi, Masahito Uchihara, Shinya Kobayashi, Masanori Matsumoto, Hideo Yagi

Blood (2024) 144 (Supplement 1): 6513.

https://doi.org/10.1182/blood-2024-202897

Published: 2024

Journal Articles

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Blood (2023) 142 (Supplement 1): 2636.

https://doi.org/10.1182/blood-2023-179316

Published: 2023

Journal Articles

Persistent ADAMTS13 Inhibitor May Lead to Delayed ADAMTS13 Recovery in Japanese Patients with Caplacizumab-Treated Immune-Mediated Thrombotic Thrombocytopenic Purpura

Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Shinya Kobayashi, Hideo Yagi, Masanori Matsumoto

Blood (2023) 142 (Supplement 1): 695.

https://doi.org/10.1182/blood-2023-179143

Published: 2023

Journal Articles

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Blood (2023) 142 (Supplement 1): 691.

https://doi.org/10.1182/blood-2023-184580

Published: 2023

Journal Articles

Post Hoc Analysis of a Phase 2/3 Study in Japanese Patients with iTTP Treated with Caplacizumab

Kazunori Imada, Yoshitaka Miyakawa, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Yasuhiro Hashimoto, Masashi Nishimi, Sayaka Tahara, Masanori Matsumoto

Blood (2023) 142 (Supplement 1): 5428.

https://doi.org/10.1182/blood-2023-180796

Published: 2023

Journal Articles

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

Blood (2023) 142 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2023-185053

Published: 2023

Journal Articles

ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Kazuya Sakai, Masanori Matsumoto, Laure De Waele, Charlotte Dekimpe, Eriko Hamada, Masayuki Kubo, Claudia Tersteeg, Simon F De Meyer, Karen Vanhoorelbeke

Blood (2022) 140 (Supplement 1): 2790–2791.

https://doi.org/10.1182/blood-2022-159415

Published: 2022

Journal Articles

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Erika Tarasco, Kenneth D. Friedman, James N. George, Paul Knöbl, Ingrid Hrachovinova, Masanori Matsumoto, Reinhard Schneppenheim, Anne Sophie Von Krogh, Bernhard Lammle, Johanna A. Kremer Hovinga Strebel

Blood (2022) 140 (Supplement 1): 336–337.

https://doi.org/10.1182/blood-2022-168612

Published: 2022

Journal Articles

Differential Diagnosis Distinguishing Immune TTP from Septic DIC Using Plasma Levels of Haptoglobin and Factor XIII Activity

Shinya Yamada, Masayuki Kubo, Eriko Hamada, Kenki Saito, Masaki Hayakawa, Hidesaku Asakura, Masanori Matsumoto

Blood (2022) 140 (Supplement 1): 2765–2766.

https://doi.org/10.1182/blood-2022-158126

Published: 2022

Journal Articles

The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study

Yoshitaka Miyakawa, Kazunori Imada, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Akihito Yonezawa, Shigeki Fujitani, Hiroshi Handa, Tadashi Matsushita, Hidesaku Asakura, Kenji Nishio, Kodai Suzuki, Yasuhiro Hashimoto, Shinobu Ohshima, Sayaka Tahara, Tomoyuki Tanaka, Masanori Matsumoto

Blood (2021) 138 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2021-148427

Published: 2021

Journal Articles

Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry

Erika Tarasco, Ralph Wendt, Anne Sophie von Krogh, Sibylle Tschumi, James N. George, Masanori Matsumoto, Paul Knöbl, Reinhard Schneppenheim, Bernhard Lämmle, other members of Hereditary TTP Registry Steering Committee, Johanna A. Kremer Hovinga Strebel

Blood (2021) 138 (Supplement 1): 770.

https://doi.org/10.1182/blood-2021-146128

Published: 2021

Journal Articles

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Erika Tarasco, Lukas Bütikofer, Kenneth D. Friedman, James N. George, Ingrid Hrachovinova, Paul N. Knöbl, Masanori Matsumoto, Anne Sophie von Krogh, Isabella Aebi-Huber, Zuzana Cermakova, Magdalena Górska-Kosicka, Katarzyna A. Jalowiec, Carlo R. Largiadèr, Zoltán Prohászka, György Sinkovits, Jerzy Windyga, Bernhard Lämmle, Johanna A. Kremer Hovinga

Blood (2021) 137 (25): 3563–3575.

https://doi.org/10.1182/blood.2020009801

Published: 2021

Includes: Supplemental data

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Blood (2020) 135 (26): 2413–2419.

https://doi.org/10.1182/blood.2020005395

Published: 2020

Includes: Supplemental data

Journal Articles

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Kazuya Sakai, MD, Masataka Kuwana, Hiroto Kojima, Hidenori Tanaka, Masayuki Kubo, Hideo Yagi, Masanori Matsumoto

Blood (2019) 134 (Supplement_1): 1085.

https://doi.org/10.1182/blood-2019-123927

Published: 2019

Journal Articles

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Anette Anette Van Dorland, PhD, Magnus Mansouri Taleghani, MD, Kenneth Dale Friedman, MD, James George, MD, Ingrid Hrachovinova, PhD, Paul Knöbl, MD PhD, Bernhard Lammle, MD, Masanori Matsumoto, MD, Anne Sophie von Krogh, MD, Reinhard Schneppenheim, MDPhD, Isabella Aebi-Huber, Bütikofer Lukas, PhD, Zuzana Cermakova, PhD, Petter Quist-Paulsen, MD PhD, Deirdra Terrell, PhD, Sara K. Vesely, PhD MPH, Yoshihiro Fujimura, MD PhD, Johanna A. Kremer Hovinga Strebel, MD

Blood (2018) 132 (Supplement 1): 376.

https://doi.org/10.1182/blood-2018-99-112095

Published: 2018

Journal Articles

Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis Formation

Kazuya Sakai, MD, Hideo Yagi, MD, Masaki Hayakawa, MD, Tatsuhiko Someya, PhD, Kaori Harada, PhD, Masanori Matsumoto, MD

Blood (2018) 132 (Supplement 1): 2522.

https://doi.org/10.1182/blood-2018-99-113948

Published: 2018

Journal Articles

Ischemia-Reperfusion Injury with Pringle's Maneuver Induces Increasing of Unusually Large Von Willebrand Factor Multimers after Hepatectomy

Takahiro Yoshikawa, MD, Takeo Nomi, MDPhD, Kazuya Sakai, MD, Masaki Hayakawa, MD, Daisuke Hokuto, MDPhD, Satoshi Yasuda, MDPhD, Masayuki Sho, MDPhD, Masanori Matsumoto, MD

Blood (2017) 130 (Supplement 1): 3608.

https://doi.org/10.1182/blood.V130.Suppl_1.3608.3608

Published: 2017

NARROW

Immediate Therapeutic Intervention for Acute Mortality in Immune-Mediated Thrombotic Thrombocytopenic Purpura with Positive Chest Findings at Initial Presentation

Post-Marketing Surveillance of the Safety and Effectiveness of Emicizumab in Japanese Patients with Congenital Hemophilia A with Inhibitors

Efficacy and Safety of Polatuzumab-Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) in the Real-World Setting: A Single Institute Retrospective Analysis

Caplacizumab Frontline Added to Therapeutic Plasma Exchange and Immunosuppression Prevents Unfavorable Outcomes in Immune-Mediated TTP: An International Real-World Study of the TTP-IWG (The Capla 500 Project)

Persistent ADAMTS13 Inhibitor May Lead to Delayed ADAMTS13 Recovery in Japanese Patients with Caplacizumab-Treated Immune-Mediated Thrombotic Thrombocytopenic Purpura

Value of Prophylactic Plasma Treatment and Incidence of Acute Episodes in Patients Enrolled in the International Hereditary Thrombotic Thrombocytopenic Purpura Registry

Post Hoc Analysis of a Phase 2/3 Study in Japanese Patients with iTTP Treated with Caplacizumab

Insight into the Natural History of Hereditary Thrombotic Thrombocytopenic Purpura: Short- and Long-Term Outcomes in a Longitudinally Followed Large Patient Cohort of the International Hereditary TTP Registry

ADAMTS13 Conformation and Immunoprofiles in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura

Neonatal Exchange Transfusion: When Should We Think about Hereditary Thrombotic Thrombocytopenic Purpura (hTTP)?

Differential Diagnosis Distinguishing Immune TTP from Septic DIC Using Plasma Levels of Haptoglobin and Factor XIII Activity

The Efficacy and Safety of Caplacizumab in Japanese Patients with Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP): An Open-Label, Phase 2/3 Study

Long-Term Renal Outcomes in Hereditary TTP Patients: Data from the International Hereditary TTP Registry

Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura

Redefining outcomes in immune TTP: an international working group consensus report

HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Inhibitory Effect of a Novel DNA Aptamer with Artificial Nucleic Bases for Von Willebrand Factor A1 Domain on Platelet Thrombosis Formation

Ischemia-Reperfusion Injury with Pringle's Maneuver Induces Increasing of Unusually Large Von Willebrand Factor Multimers after Hepatectomy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only